BridgeMD
New treatment option for Type 2 Diabetes
Official title High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes
ClinicalTrials.gov ID: NCT06688461
What this study is testing
- What it's testing
- A recognized driver for cardiovascular complications of type 2 diabetes mellitus (T2DM) is impaired plasma glucose homeostasis as consequence of skeletal muscle insulin resistance. Insulin-mediated plasma glucose disposal in skeletal muscle comprises oxidative glucose disposal (cellular glucose uptake for oxidation) and non-oxidative glucose disposal (NOGD; cellular glucose uptake for storage as glycogen), both processes being impaired in T2DM patients.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 45 to 75
You may be able to join if
- Participants are able to provide signed and dated written informed consent prior to any study specific procedures
- Aged ≥ 45 and ≤ 75 years
- BMI: 25-35 kg/m2
- Diagnosed as T2DM patients for at least 1 year and not longer than 5 years
- HbA1c ≥ 6.5% and ≤ 8.5%
You likely can't join if
- Type 1 diabetes
- Patients with congestive heart failure and and/or severe renal and or liver insufficiency
- Contraindications for MRI/MRS examination
- Active diabetic foot
- Polyneuropathy or retinopathy
- Signs of active liver or kidney dysfunction
See the full eligibility criteria
- Participants are able to provide signed and dated written informed consent prior to any study specific procedures
- Aged ≥ 45 and ≤ 75 years
- BMI: 25-35 kg/m2
- Diagnosed as T2DM patients for at least 1 year and not longer than 5 years
- HbA1c ≥ 6.5% and ≤ 8.5%
- Fasting blood glucose \<130 mg/dL
- Women are post-menopausal (\>1 year cessation of menses),
- Being stable on medication use of metformin and/or sulfonylurea derivatives for the previous 3 months or more and other medication naïve.
- Type 1 diabetes
- Patients with congestive heart failure and and/or severe renal and or liver insufficiency
- Contraindications for MRI/MRS examination
- Active diabetic foot
- Polyneuropathy or retinopathy
- Signs of active liver or kidney dysfunction
- BMI \>35 kg/m2
- Exogeneous insulin therapy
- Use of antidiabetic medication other than metformin or sulfonylurea derivatives treatment within 3 months before screening
- Use of SGLT2 inhibitors
- Unstable body weight (variations \>5kg in the last 3 months)
- Ongoing weight loss diet or use of weight loss agents
- Uncontrolled hypertension
- Engagement in regular exercise program or any other medical condition that will impede the safe performance of the experiments
The study team makes the final eligibility decision.
Where it's taking place
- Santiago, Chile
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 45 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Santiago, Chile. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.